January is cervical cancer awareness month. Roche is committed to cervical cancer prevention and is proud to announce that the new Roche cobas® HPV assay for use on the cobas® 6800/8800 Systems is now Health Canada approved
More than 99 percent of cervical cancers are caused by a persistent high-risk HPV infection1
cobas HPV assay helps to provide critical screening in identifying women at risk, before pre-cancer or cancer develops
cobas 6800/8800 Systems deliver full automation, helping laboratories meet the throughput that high volume, HPV DNA screening programs demand
LAVAL, QC, Jan. 31, 2019 /CNW/ - Roche Diagnostics receives Health Canada Authorization to Market the cobas® HPV on the cobas® 6800/8800 Systems for cervical cancer screening in Canada.
Human Papillomavirus (HPV) is a known cause of cervical cancer and is used to identify women at risk. This HPV DNA assay adds to the growing Canadian-IVD menu on the cobas® 6800/8800 Systems, and gives laboratories the ability to run HPV DNA testing simultaneously with other previously released cobas assays including: HIV-1, HCV, HBV, CMV, DPX plus two donor screening assays cobas® MPX, and cobas® WNV.
As demonstrated by the prospective clinical study "ATHENA2" comparing screening strategies using cobas® HPV test on the cobas® 4800 System, screening with the HPV test detects more high-grade disease than a Pap test alone. Identifying women at risk, before pre-cancer or cancer develops, is an important prevention strategy as it helps maintain screening efficiency and helps protect women from the potential harms of overtreatment. Countries are increasingly looking to adopt the detection of HPV DNA as primary screening tool instead of the Pap test as part of their national cervical cancer programs3.
"As territorial and provincial screening programs and laboratories look toward introducing HPV for primary screening, they require systems that provide the highest performance standards that Roche delivers as well as new ways to increase efficiency, which ultimately benefit everyone receiving or providing health care across the country" said Whitney Green, President and General Manager, Roche Diagnostics, division of Hoffmann-La Roche Limited, Canada. "In addition to the powerful clinical benefits of the cobas® HPV test, Roche now caters to the needs of both low-to-mid volume labs and high-throughput labs in Canada who want to consolidate a multitude of validated assays onto a single platform."
The fully automated cobas® 6800/8800 Systems provide the fastest turn-around time, highest throughput and the longest walk-away time compared to other automated molecular platforms, giving laboratories the flexibility to adapt to changing testing demands.
About the Roche Cervical Cancer Portfolio The Roche Cervical Cancer Portfolio enables healthcare professionals to better screen, manage and diagnose women, based on the confidence and clarity of results across a continuum of patient care. The unique combination of molecular, cellular and tissue-based diagnostic tests provides healthcare professionals powerful information to make patient care decisions and minimize unnecessary treatment. cobas® HPV testing is clinically validated for HPV primary screening, ASC-US triage, or co-testing (HPV and Pap cytology) using the cobas® 4800 or cobas® 6800/8800 Systems. The cobas® HPV assays provide specific genotyping information for HPV 16 and HPV 18, the highest-risk types, while simultaneously reporting the 12 other high-risk HPV types as a pooled result, all in one test and from one patient sample. More information about cobas® HPV is available at http://www.rochecanada.com/. Using advanced, dual-biomarker technology to simultaneously detect p16 & Ki-67, CINtec® PLUS Cytology* definitively identifies transforming HPV infections, providing greater certainty to clinicians to stratify patients for follow-up or intervention. CINtec® PLUS Cytology* is an objective triage solution for managing HPV-positive or abnormal Pap cytology primary screening results and helps address some of the limitations of traditional Pap cytology. CINtec® Histology is used to confirm the presence or absence of high-grade cervical disease in women who have had a tissue biopsy. CINtec® Histology uses the p16 biomarker for a more conclusive diagnosis to provide distinctive visual confirmation of pre-cancerous cervical lesions that may be missed by H&E or morphologic interpretation alone. Both CINtec® assays have been fully automated on the VENTANA BenchMark IHC/ISH instruments.
About the cobas 6800/8800 Systems The cobas® 6800 and cobas® 8800 systems are fully integrated, automated solutions that introduce a new standard for routine molecular testing in the areas of viral load monitoring, donor screening, women's health and microbiology. Based on Nobel prize-winning PCR technology, the systems are designed to deliver full automation, increased throughput and faster turnaround time, providing users with greater flexibility to increase overall workflow efficiencies. The systems provide up to 96 results in less than 3.5 hours and a total of 384 results for the cobas 6800 System and 960 results for the cobas 8800 System in an eight-hour shift. For more information about the Systems, visit http://www.rochecanada.com
References
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189:12-19.
MH, Wright TC, Sharma A, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135(3):468-475.
About the Roche Group Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
SOURCE Roche Diagnostics
Home Care Ontario Welcomes Release of the Premier's Council on Improving Healthcare and Ending Hallway Medicine First Report
Report's focus on strengthening home care good news for patients
TORONTO, Jan. 31, 2019 /CNW/ - Home Care Ontario, the voice of home care in OntarioTM, welcomes today's release of the first report from the Premier's Council on Improving Health Care and Ending Hallway Medicine. The report underscores the need for changes to our health system which will be good news for patients and caregivers alike.
"We welcome today's report from the Premier's Council as an important step to ending hallway health care and improving Ontario's health care system," said Sue VanderBent, CEO, Home Care Ontario. "We are pleased to see the Council recognizes the key role that home care can play in ending hallway health care and delivering real results for patients."
Home Care Ontario believes that we can end hallway health care and hospital overcrowding in Ontario by making professional home care services more widely available for patients and their families. The Association fundamentally agrees with the Council's report where it states:
"Solving hallway health care will not just be a matter of adding more beds to the system. Increasing capacity in the community, staffing levels, training, and support will play an important role in building a high-functioning system that works for all Ontarians – including the ones who work in health care."
Delivering more care at home would help end hallway health care by keeping people out of emergency departments, getting people home sooner, and giving people more control over their care. By effectively using home care in this way, we can help end hallway health care and ultimately create a stronger health care system.
"Transforming Ontario's health care system to put home care at its centre will be essential to ensuring we can provide quality care for patients today and for decades to come," concluded VanderBent. "Home Care Ontario looks forward to working with the Premier's Council, and the government as it looks for ways to make this vision a reality."
Major donation makes free relief childcare to Kingston mothers with cancer possible
Non-profit Nanny Angel Network set to provide its unique services starting this Summer, thanks to a $300K donation from Homestead Land Holdings
KINGSTON, ON, Jan. 31, 2019 /CNW/ - Britton Smith, Philanthropist and Executive Chairman of Homestead Land Holdings presented the Nanny Angel Network (NAN) with a $300,000 donation that will bring free, specialized, relief childcare to Kingston mothers with cancer. This donation will see NAN's first expansion outside of the Greater Toronto Area, to Kingston.
"The Nanny Angel Network is incredibly grateful for this financial commitment," said Audrey Guth, NAN founder and cancer survivor. "We are looking forward to becoming a part of the Kingston community and bringing much-needed relief for moms with cancer and compassionate support for their children."
Families coping with cancer face a number of challenges and NAN's specially trained volunteer Nanny Angels have one goal in mind – lessening the impact of cancer on families. Each family is matched with a volunteer who visits weekly and engages the children in fun, interactive activities while their mom rests, attends treatment, or takes the time for herself.
NAN volunteers have experience working with children and undergo specialized training focused on how to talk to children about cancer, and death and dying. This equips them to support families by reducing any fear and anxiety the children may be experiencing as a result of their mother's illness.
"The impact of this donation from Britton Smith and Homestead Land Holdings will live on for generations, as we continue to support children through our therapeutic program," said Guth.
The donation is a part of a proud legacy of giving by Britton Smith and Homestead Land Holdings in the Kingston community and beyond.
"Homestead Land Holdings tries to give back to the community and is proud to support the Nanny Angel Network's expansion into Kingston," said Britton Smith, Philanthropist and Executive Chairman of Homestead Land Holdings. "We know that cancer not only impacts the patient, it impacts the entire family and we are pleased to lend support to moms with cancer and their children."
NAN plans to open its Kingston office in Summer 2019. To learn more about NAN, apply to become a Nanny Angel, or make a donation, please visit: nannyangelnetwork.com
PHOTO: l-r: Leah Werry, NAN Kingston Champion, and Audrey Guth, NAN Founder, accept a $300,000 donation from Britton Smith, Homestead Land Holdings, Executive Chairman and Scott Topping, Homestead Land Holdings, Chief Operating Officer.
ABOUT NAN: NAN provides free childcare support throughout a mother's recovery or during the palliative care and bereavement period through volunteer Nanny Angels. These volunteers are specially-trained by NAN to help children navigate their moms' cancer.
During visits, Nanny Angels arrive with fun age-appropriate activities designed to engage children, help bring a sense of normalcy back to their lives and reduce stress and anxiety the child may be experiencing. NAN volunteers have professional designations, including: teachers, early childhood educators, social workers, nurses, professional nannies and students from education and medical programs.
Since NAN was founded in 2009, it has supported hundreds of families in the Greater Toronto Area, providing more than 22,000 hours of service, almost 7,000 total visits, supporting more than 750 families. Click here for impact video.
ABOUT THE FOUNDER: Audrey Guth was diagnosed with breast cancer in 2008 when she was a wife, mother of four children and entrepreneur. During her treatment, she observed many young mothers struggling to manage the demands of treatment with the never-ending needs of their families. It was then that the Nanny Angel Network was conceived. Audrey Guth was named a L'Oreal Paris Canada Woman of Worth honouree in 2017 and was named a CNN Hero in 2014.
SOURCE Nanny Angel Network
‘Gym dates’ the perfect solution for multitasking singles
Juggling the demands of work, errands, spending time with friends and family, plus exercising regularly, more Canadian singles are finding themselves with no time for romance. Now, more people are choosing the gym as their favourite dating venue. Working out is a great way to spend fun, informal time together and can be the most convenient option for stressed-out singles. It’s not surprising that millennials are the most likely demographic to find romance at the gym. Six out of 10 say they prefer to meet romantic partners through shared interests. And fitness is a huge interest among that cohort -- nearly nine out of 10 (87%) work out more than once a week. Not only that but millennials are lonely and tired of dating – they’re 65 percent more likely to feel lonely and 36 percent more likely to feel burned out by dating.
A gym date sounds like the perfect answer. Exercising together reveals important details about your date - you learn about their work ethic, ability to have fun and maybe even how they respond to instructor input during a fitness class. Physical activity with a potential partner is also a great way to amplify attraction. In fact, the body reacts to exercise in the same way as it does when we feel attracted to another person – our palms sweat, our face flushes, and our heartbeat speeds up. Even better, studies show that when we exercise with someone who we find attractive, we get more from our workout. And we’re more likely to choose a romantic partner who shares an interest in being active. But a gym date can go badly if you don’t plan ahead. Here are some dos and don’ts for the perfect gym date:
• If you’re choosing a group fitness class, DO pick one that’s suitable for multiple skill levels.Yoga, spin or dance-inspired classes like BODYJAM are great options. Most gyms allow members to bring a guest.
• Do dress to impress. Gym clothes that are functional and presentable are key. Consider buying a new outfit. It might serve as a confidence boost.
• Choose cardio if you want to chat. If you’re looking to get to know each other better, consider doing some cardio to have more time to chat. If you’d rather not make small talk, opt for a group fitness class where you can only talk before and after the workout.
• Don’t try to exercise for too long. Aim for 45 minutes at first. If you go much longer, you’ll be too tired and sweaty to enjoy the rest of your date.
• Don’t objectify your date. Feel free to comment if they seem strong or fit, but don’t go overboard, and don’t stare.
• Do check your ego at the door. Show you’re fit but try not to show off. The date won’t go well if you seem full of yourself.
• Don’t wear headphones. The goal is to have fun with your date. Save the beats for solo time.
• Don’t do PDAs. Remember you’re in a public place. Try not to make those around you feel uncomfortable.
• Do plan for a meal or drink after the workout. This will be your chance to really get to know each other and rehash the highlights of your sweat session.
High-dose radiation therapy improves long-term survival in patients with stage-IV cancers, trial finds
Key Takeaway: “We've taken patients with a shorter life expectancy and achieved complete or partial remission for a significant number of them. Moreover, their overall survival has been maintained without adversely affecting their quality of life.” --Dwight E. Heron, MD, MBA, FACRO, FACR, Professor and Director of Radiation Services, UPMC Hillman Cancer Center
ARLINGTON, Va., January 31, 2019 — The first report from a phase II, multi-center clinical trial indicates that a newer, more aggressive form of radiation therapy — stereotactic radiation — can extend long-term survival for some patients with stage-IV cancers while maintaining their quality of life. The study is published in the January issue of International Journal of Radiation Oncology • Biology • Physics (Red Journal), the flagship scientific journal of the American Society for Radiation Oncology (ASTRO).
“Despite many advances in cancer care over the last 20 to 30 years, some patients still go on to develop metastatic or stage-IV disease. Generally speaking, radiation therapy in that setting has been used only to make the patient comfortable,” said Dwight E. Heron, MD, MBA, FACRO, FACR, senior author of the study and director of radiation services at UPMC Hillman Cancer Center in Pittsburgh.
“It also has been the case, however, that a small number of patients with stage-IV disease could have surgery to remove their metastases and live a long time. And so our question was, could we use highly focused radiation to destroy those tumors and have the same effect as surgery? The initial answer from this large prospective trial is yes.”
Patients in the trial were treated with stereotactic radiation, which is a form of high-precision cancer therapy that delivers substantially higher doses of radiation to the tumor site in one to five treatment sessions. Increasing evidence points to stereotactic radiation as a viable alternative when patients cannot undergo surgery to remove metastatic tumors.
“With stereotactic radiation, we use a different type of highly precise local therapy to target tumors in the lungs, liver, bones or kidneys with precision that is analogous to surgery, and with very few side effects or harm to the patient's quality of life,” said Dr. Heron, who is also a professor of radiation oncology, otolaryngology and head and neck surgery at the University of Pittsburgh School of Medicine.
In this phase II trial, Dr. Heron and his colleagues enrolled 147 patients across three large cancer centers to evaluate the safety and feasibility of stereotactic radiation for a variety of oligometastatic cancers — that is, cancers that had been previously treated but then returned in a limited number of other parts of the body. Each patient had up to five metastases — most had either one (71%) or two (19%) — in one to three new sites. The metastases were located most commonly in the lung (52%), followed by lymph nodes (16.5%), bone (15%) or liver (7%).
All patients received stereotactic radiation to all metastatic sites. Radiation dosing and fractionation were dependent on the size and location of each metastasis. All patients had good performance status (ECOG 0-1) and a life expectancy of more than 6 months. Median follow-up time for this report was 41 months (range=14.6-59.0).
Following treatment with stereotactic radiation, more than eight in ten patients (84%) survived at least 1 year, and four in ten (43%) survived 5 years or longer. The median overall survival (OS) time was 42.3 months.
Local recurrences were uncommon; half of the patients experienced complete (26%) or partial (26%) remission following treatment. An additional third (32%) had stable disease, meaning their cancer did not progress or recede. The remaining patients either had local progression following treatment (14%) or their response could not be determined (12%). Distant recurrences were more common, with a median time of 8.7 months until distant progression. The one-year and five-year rates of distant progression free survival (DPFS) were 44 percent and 17 percent, respectively.
The type of primary tumor was associated with both OS (p=0.002) and DPFS (p=0.008). Patients with primary breast (9% of patients), prostate (7.5%) and colorectal (21%) tumors had longer survival than those with primary lung (22%) or head and neck (11%) tumors.
Severe side effects were limited. Just under 10 percent of patients experienced short-term toxicity of grade-2 or higher, including one grade-3 case each of labored breathing, skin inflammation and anemia. Even fewer patients had severe long-term toxicity, with one grade-3 ureter obstruction and one grade-4 obstruction of the small bowel.
A unique aspect of the trial design was the decision to use patient-reported rather than physician-assessed quality of life (QoL). Patients reported no significant changes in their quality of life immediately after completing stereotactic radiation, nor at 6 weeks, 3 months and 9 months follow-up. At the 6- and 12-month marks, QoL was significantly better than before treatment.
“Many of the cancer treatments we deliver, even though they have a therapeutic benefit, also are associated with some toxicity, and that may impact patients’ quality of life. In this study, for patients with stage-IV disease, we have a treatment paradigm that can result in long-term survival while maintaining overall quality of life. We had a sense this was the case from retrospective data, but the addition of prospective data is very convincing,” said Dr. Heron.
Dr. Heron said his team plans to continue enrolling patients into the trial, with a goal of expanding the current 147 patients to roughly 200 total patients. Moving forward with additional trials, they also will look at treating patients with larger numbers of metastatic lesions and combining stereotactic radiation with emerging treatments such as immunotherapy.
“In combination with immunotherapy, stereotactic radiation therapy may set a new bar for achieving better outcomes, lowering side effects and improving our patients’ quality of life,” said Dr. Heron.
This trial adds to the growing body of evidence supporting the use of stereotactic radiation for oligometastatic cancers. Two randomized, phase II trials presented at the most recent ASTRO Annual Meeting, for example, also found the treatment may lengthen survival, sometimes dramatically, for patients with stage-IV disease. If validated through larger randomized trials, radiation therapy could be utilized as a safe and effective approach to improve outcomes for patients with cancers that have begun to spread throughout the body.
Article Details
Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer
Authors: Philip Sutera, BS, David A. Clump, MD, PhD, Ronny Kalash, DO, David D'Ambrosio, MD, Alina Mihai, MD, MSc, Hong Wang, PhD, Daniel P. Petro, MD, Steven A. Burton, MD, Dwight E. Heron, MD, MBA
International Journal of Radiation Oncology • Biology • Physics, Volume 103, Issue 1, pages 116-122
The American Society for Radiation Oncology (ASTRO) is the world’s largest radiation oncology society, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology • Biology • Physics, Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, RT Answers; and created the nonprofit foundation Radiation Oncology Institute. To learn more about ASTRO, visit astro.org or RTanswers.org, sign up to receive our news and follow us on our blog, Facebook,Twitter and LinkedIn.
Kathleen Trotter Personal Trainer, Nutritionist, and Life Coach
Wants You to BecomeYOUR FITTEST FUTURE SELFAdopting a healthier lifestyle often feels overwhelming and draining — like a chore. The trick to sustaining a lifestyle change long term is reframing the creation of your health mixes.In YOUR FITTEST FUTURE SELF, author and fitness expert Kathleen Trotter advises readers to think of creating mixes like going on an adventure or figuring out a puzzle rather than as something overwhelming, exhausting, or “yet another obligation.” Kathleen encourages readers to stop thinking of “past health experiences” as something to be frustrated about. Past experiences are data — information to be learned from. Her advice is that if you know an element of a diet or a type of workout absolutely didn’t work for you, don’t add that element to your mix. If you loved a particular element of a diet or a past activity — playing a sport or dancing at clubs — consider joining a team or taking dance classes. Learn from your past experiences so you can create, now, a mix that suits you, leading to that fitter self. Have fun learning about yourself and if, at first, the pieces don’t fit together, try to figure out why and try again. You can do this! Drive the bus of your own life instead of letting the bus drive you. Lean-in to your health and start working for what you want. Your fittest future self is waiting — get excited!
Kathleen Trotteris a fitness expert, media personality, personal trainer, writer, life coach, certified Pilates and ELDOA instructor, and overall health enthusiast. Her passion is motivating others to “find their fit” and works with clients ranging from endurance athletes to individuals living with Parkinson’s disease and osteoporosis. She also writes for the Globe and Mail and Huffington Post, blogs for Flaman Fitness, and makes regular TV appearances. Kathleen holds an M.Sc. from the University of Toronto and a nutrition diploma from the Canadian School of Natural Nutrition. She lives in Toronto where she owns a personal training studio.Find out more about Kathleen at www.KathleenTrotter.com. FACEBOOK | INSTAGRAM | TWITTERCLICK HERE FOR PRESS KIT
SUGGESTED TALKING POINTS:Your new book is “Your Fittest Future Self”. What does that mean?What is an “individualized health mix”?Can you tell us a little bit more about the “mix concept”?You believe that when it comes to fitness that there is not a one-sized solution that fits all. What does that mean for the reader?What would you say is the biggest setback people meet on their journey to a healthy lifestyle?Understanding that we are all different and that we need to create a unique plan for ourselves, where does one start?What is the most important tool for a person beginning their fitness journey?You mention the concept of the “NUTRITIONmix”. What are the foundations of a healthy “NUTRITIONmix”?What is the one thing people don’t get enough of on their journey to being their fittest future self?How important gut health and glycemic index on the path to “Your Fittest Future Self”?areWhat do you mean when you suggest “rethinking fit”?What are some strategies that someone would use if they wanted to “rethink fit”?Is daily exercise vital to our success or will a few times per week work just fine?
Is Underwear A Good Valentines Gift For Men? January 30, 2019 – Valentine’s Day! That made up ‘Hallmark’ holiday that sends men and women into a last-minute frenzy of gift selection every February fourteenth. With Valentine’s Day a couple of weeks away, SwampButt Underwear (www.swampbutt.com) askes the question; what if anything should a woman get for the man in their lives and which one of these credit cards is still good after December 25, 2018, 2017, 2016? A 69 Percent Solution for Valentine’s DayAssuming any of these women still have money, SwampButt Underwear recommends its Red and White pairing and is offering a special for Valentine’s Day with both pairs available for $34.69, a full $15.29 off the regular price. View the product pairing here: Valentine’s Day Red and White Sale.The company will also honor gift cards in the amount of $34.69 for the red and white pairing and issued a special card for the occasion. “The difference between the regular price for 2 pairs of SwampButt Underwear ‘Made In The USA’ variety and the sale price is really 30.5%,” said SwampButt Underwear spokesperson and serial divorcee, Nick Heraldson. “But $34.69 is 69% of the regular price and we really wanted to get the ‘69’ reference in there because it was more romantic sounding.” Here is a link to the gift card: Valentine’s Day Gift Card. Say No To Lace & Frills For DudesIs the gift of lingerie for men acceptable? In Heraldson’s opinion it is not. “Lingerie on men is a non-starter for me and for most of the women I know,” Heraldson said. “What guys do or wear or don’t wear in private is strictly none of my business.” But according to Heraldson and the people he asked in the break room, regular, really good underwear as a gift for men is perfectly okay. Acknowledging that he works for a company that only makes underwear for men gave Heraldson no pause or any time for self-reflection. “Hey, everyone likes a shill,” he said confidently. Not A Day for LosersOf course, Valentine’s day is a sad day for many as they think of all the stuff they did not get for Christmas, are between boyfriends/girlfriends, or for those who are emotionally incompatible with members of the opposite sex, the same sex, or other humans in general and dogs or cats. “It should be ‘gender’ and not ‘sex’,” Heraldson muttered before he went on. “You see a lot of singles at the movies on Valentine’s day. Sitting alone, hiding in the dark so no one from work will see me.” Take advantage of the Red and White Valentine’s Day special and pay $34.69 instead of $49.98 now through February 14, 2019 or before the owner changes his mind. Shipping is free anywhere in the lower 48 states. Losers like Nick are always welcome. About SwampButt UnderwearSwampButt Underwear is a real company that makes a product to help solve a problem; visible sweat on a man’s posterior. SwampButt Underwear™ is trademarked in the USA and foreign countries. We paid a lot for it so please do not use it without written permission.
DeafBlind Ontario Services urges recognition of the universal rights of individuals who are deafblind
DeafBlind Ontario Services believes that individuals who are deafblind deserve the opportunity to express their needs, communicate effectively and build the life skills needed to truly thrive in their communities in alignment with the United Nations' Convention on the Rights of Persons with Disabilities, and recommendations from a World Federation of the Deafblind's report, At Risk of Exclusion from CRPD and SDG's Implementation: Inequality and Persons with Deafblindness.
According to the World Federation of the Deafblind's report, between 0.2% and 2% of the world's population is deafblind. Based on the 2017 Canadian Survey on Disability Data, released on November 28, 2018, it is estimated that the prevalence rate is 1.66% of the total population in Canada (28,008,860) for those 15 years and over who have reported vision and hearing disabilities combined that restricts their activities of daily living.
While individuals who are deafblind represent a small segment of the global population, they are likely to face challenges finding and obtaining appropriate professional supports. As a result, they are often excluded from development and support programmes.
Founded in 1989, DeafBlind Ontario Services is a not-for-profit organization that helps individuals who are deafblind increase their independence and improve their quality of life through specialized services. With programs and services across the province, their services extend into a wide range of communities in Ontario.
For Immediate Release The information contained in this release is protected by copyright. Members of the media may may sign up for embargoed news or to request a copy of any study please contact: Penny Smith +44 (0) 1243 770448 (UK)Josh Glickman +1 201-748-6572 (US) newsroom@wiley.com Follow us on Twitter @WileyNewsStudy Examines Long-Term Opioid Use in Patients with Severe Osteoarthritis New research published in Arthritis & Rheumatology, an official journal of the American College of Rheumatology, reveals that prescription opioids are commonly used long-term to treat pain in older patients with severe osteoarthritis. The study also found substantial statewide variation in rates of treatment with long-term opioid therapy for osteoarthritis, which was not fully explained by differences in patient characteristics or access to healthcare providers. Long-term use of prescription opioids for the treatment of chronic pain carries the risk of dependence and other serious harms. Osteoarthritis in the hip or knee is a common source of chronic pain in the United States, as it affects nearly 30 million US adults and has a prevalence that is expected to rise with the aging of the population. To evaluate long-term opioid use in patients with severe osteoarthritis and to examine differences based on geography and healthcare access, Rishi J. Desai, MS, PhD, of Brigham and Women’s Hospital and Harvard Medical School, and his colleagues analyzed 2010–2014 Medicare data on osteoarthritis patients undergoing total joint replacement. The analysis included 358,121 patients with an average age of 74 years. One in six patients used long-term prescription opioids (≥90 days) for pain management in the year leading up to total joint replacement, with an average duration of approximately seven months. More strikingly, nearly 20 percent of the long-term users consumed an average daily dose of ≥50 morphine milligram equivalents, an amount that was identified by recent guidelines as potentially imparting a high risk of opioid-related harms. The average percent of long-term opioid users among advanced osteoarthritis patients varied widely across states, ranging from 8.9 percent in Minnesota to 26.4 percent in Alabama. Access to primary care providers was only modestly associated with rates of long-term opioid use (an average adjusted difference of 1.4 percent between areas with highest versus lowest concentration of primary care providers), while access to rheumatologists was not associated with long-term opioid use. “These findings suggest that regional prescribing practices are key determinants of prescription opioid use in chronic pain patients, and geographically targeted dissemination strategies for safe opioid prescribing guidelines may be required to address the high use observed in certain states,” said Dr. Desai.Additional informationThe information contained in this release is protected by copyright. Members of the media may sign up for embargoed news or to request a copy of any study please contact: Penny Smith +44 (0) 1243 770448 (UK)Josh Glickman +1 201-748-6572 (US) newsroom@wiley.com Follow us on Twitter @WileyNewsFull Citation: “Association of geography and access to healthcare providers with long term prescription opioid use in Medicare patients with severe osteoarthritis: A cohort study.” Rishi J. Desai, Yinzhu Jin, Patricia D. Franklin, Yvonne C. Lee, Brian T. Bateman, Joyce Lii, Daniel H. Solomon, Jeffrey N. Katz, and Seoyoung C. Kim. Arthritis & Rheumatology; Published Online: January 28, 2019 (DOI: 10.1002/art.40834).URL Upon Publication: http://doi.wiley.com/10.1002/art.40834Author Contact: Marck Murphy, BWH Media relations manager, at mmurphy90@bwh.harvard.edu. About the Journal Arthritis & Rheumatology is an official journal of the American College of Rheumatology (ACR) and covers all aspects of inflammatory disease. The American College of Rheumatology (www.rheumatology.org) is the professional organization whose members share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. The journal is published by Wiley on behalf of the ACR. For more information, please visit http://wileyonlinelibrary.com/journal/art.
About Wiley Wiley is a global leader in research and education. Our online scientific, technical, medical, and scholarly journals, and our digital learning, assessment, certification and student-lifecycle services and solutions help universities, academic societies, businesses, governments and individuals to achieve their academic and professional goals. For more than 200 years, we have delivered consistent performance to our stakeholders. The Company's website can be accessed at www.wiley.com.
Dr. Levi Inspires Audiences To Adopt Fitness As A Lifestyle
Los Angeles, CA, January 29, 2019 ― Dr. Levi Harrison is hoping that people everywhere will resolve to make 2019 their healthiest year yet by incorporating fitness into their daily lives in a way that is both effective and sustainable. True fitness is about much more than a gym membership, Dr. Levi emphasizes. It's about adopting a lifestyle that balances mind, body, soul and spirit.
Dr. Levi is an orthopedic surgeon specializing in hand, wrist and shoulder injuries. He is passionate about overall health and fitness and has developed a multi-faceted, multi-media approach to sharing his healthy lifestyle strategies.
His first book, The Art of Fitness: A Journey to Self Enhancement, is an encyclopedia of core-stabilizing and body-building exercises, with easy-to-follow instructions and photographs.
The DVD, The Art of Fitness Cardio Core Workout, is a great accompaniment to the book. The DVD demonstrates aerobic, core and abdominal exercises that can elevate and improve any fitness level, with a bonus workout, Perfect Abs, for those who want additional abdominal work.
Dr. Levi also provides ESPORTS coaching, motivational speaking and nutritional counseling.
Dr. Levi Harrison earned his medical degree at The University of California at Davis School of Medicine and completed his fellowship at the internationally renowned Indiana Hand to Shoulder Center in Indianapolis. His practice in Los Angeles is a center of excellence for sports-related upper extremity and shoulder injuries as well as hand rehabilitation.
He has appeared as a medical authority on The Dr. Oz Show, CNN, Fox TV, Studio 11 LA and the KTLA Morning News. Dr. Levi has also been featured in multiple gaming communities, including Yahoo Games, Kotaku, Geek & Sundry, Vice's Motherboard, Machinima, IGN, XM Radio and countless others for his groundbreaking work in preventing repetitive stress injury in the competitive ESPORTS community.
The Art of Fitness: A Journey to Self Enhancement Publisher: Brio Press ISBN-10: 1937061825 ISBN-13: 978-1937061821 Available from Amazon.com. Available from http://drleviharrison.com/.
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
